Nucleic acids in human glioma treatment: innovative approaches and recent results.
Gliomas are the most common primary central nervous system tumors with a dismal prognosis. Despite recent advances in surgery, radiotherapy, and chemotherapy, current treatment regimens have a modest survival benefit. A crucial challenge is to deliver drugs effectively to invasive glioma cells residing in a sanctuary within the central nervous system. New therapies are essential, and oligonucleotide-based approaches, including antisense, microRNAs, small interfering RNAs, and nucleic acid aptamers, may provide a viable strategy. Thanks to their unique characteristics (low size, good affinity for the target, no immunogenicity, chemical structures that can be easily modified to improve their in vivo applications), these molecules may represent a valid alternative to antibodies particularly to overcome challenges presented by the blood-brain barrier. Here we will discuss recent results on the use of oligonucleotides that will hopefully provide new effective treatment for gliomas.
Istituto per l'Endocrinologia e l'Oncologia Sperimentale del CNR "G. Salvatore", Via Pansini 5, 80131 Naples, Italy.
S
S
Catuogno
C L
CL
Esposito
C
C
Quintavalle
G
G
Condorelli
V
V
de Franciscis
L
L
Cerchia